The private label CBD gummies market is poised for significant expansion, with projections indicating it will reach USD 1,382.2 million by 2036, according to a new report from Future Market Insights (FMI). Valued at USD 598.9 million in 2025, the market is expected to grow to USD 646.2 million in 2026 and register a compound annual growth rate (CAGR) of 7.9% over the next decade.
Market growth is being fueled by a shift among wellness brands toward outsourced manufacturing, as companies seek to reduce capital investment and accelerate time-to-market for CBD edible products. White label production models, which allow brands to leverage existing formulations and manufacturing capabilities, are particularly popular. In 2026, white label gummies are projected to account for 46.2% of global demand, enabling new entrants to focus on branding and marketing rather than product development.
“Private label CBD gummies provide wellness brands with a faster and more efficient route into the expanding CBD edibles market,” said Nandini Roy Choudhury, Principal Consultant for Food & Beverage at Future Market Insights. “Going forward, competitive advantage will increasingly depend on suppliers that combine formulation expertise with comprehensive testing, compliant labeling, and retail-ready documentation.”
Broad-spectrum CBD gummies are leading the market by spectrum type, capturing 42.8% of demand in 2026. Consumer preference for THC-free products with multiple cannabinoids is driving this trend, as retailers and regulators place greater emphasis on product safety and transparency. Brand websites remain the dominant sales channel, representing 39.6% of global demand, as direct-to-consumer platforms enable better customer education and subscription-based purchasing.
The United States is expected to be the fastest-growing market, with a CAGR of 8.5% through 2036, supported by a mature CBD ecosystem and strong direct-to-consumer infrastructure. Other key markets include Canada (8.1% CAGR), the United Kingdom (7.8%), and Germany (7.5%).
Despite strong growth prospects, the market faces regulatory challenges, including varying CBD health claim rules and labeling requirements across countries. However, increasing investment in third-party testing, batch traceability, and clean-label product development is helping brands navigate these complexities.
Key players in the market include CBD Nationwide, Extract Labs, cbdMD, Inc., Charlotte’s Web Holdings, Inc., CV Sciences, Inc., Medterra CBD LLC, British Cannabis, Cannaray Limited, MediPharm Labs Corp., and Little Green Pharma Ltd. These companies are competing on formulation expertise, manufacturing scalability, and compliance support.
For more detailed market forecasts and competitive benchmarking, access the full report at https://www.futuremarketinsights.com/reports/sample/rep-gb-33370.
